Indacaterol and Glycopyrrolate and Verapamil Extended Release Tablets
Determining the interaction of Indacaterol and Glycopyrrolate and Verapamil Extended Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter. When a single 300 mcg dose of indacaterol inhalation powder was administered in combination with the potent dual CYP450 3A4/P-glycoprotein inhibitor, ketoconazole (200 mcg twice daily for 7 days), indacaterol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.3- and 1.9-fold, respectively. These changes probably reflect the impact of maximal combined inhibition. Similarly, verapamil 80 mg three times a day for 4 days increased indacaterol Cmax by 1.5-fold and AUC by 2-fold, while erythromycin 400 mg four times a day for 7 days increased indacaterol Cmax by 1.2-fold and AUC by 1.4-fold. Ritonavir 300 mg twice daily for 7.5 days had no effect on the Cmax of indacaterol, but increased its AUC by 1.7-fold. Indacaterol oral inhalation powder has been evaluated in clinical trials for up to one year at doses up to 600 mcg. No dosage adjustment is necessary at the 75 mcg dose when used with CYP450 3A4 and P-glycoprotein inhibitors.
- "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: glycopyrrolate / indacaterol
Brand name: Utibron Neohaler
Synonyms: Glycopyrrolate and indacaterol (inhalation)
Generic Name: verapamil
Brand name: Calan, Isoptin SR, Verelan, Isoptin, Calan SR, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Verapamil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Indacaterol and Glycopyrrolate-Verapamil Hydrochloride
- Indacaterol and Glycopyrrolate-Verapamil Hydrochloride PM
- Indacaterol and Glycopyrrolate-Verapamil Immediate-Release Tablets
- Indacaterol and Glycopyrrolate-Verapamil Injection
- Indacaterol and Glycopyrrolate-Verapamil Intravenous
- Indacaterol and Glycopyrrolate-Verapamil Long-Acting Capsules
- Verapamil Extended Release Tablets-Indacaterol and glycopyrrolate Inhalation
- Verapamil Extended Release Tablets-Indacaterol inhalation
- Verapamil Extended Release Tablets-Indacaterol Maleate
- Verapamil Extended Release Tablets-Indapamide
- Verapamil Extended Release Tablets-Inderal
- Verapamil Extended Release Tablets-Inderal Intravenous